Overall, these data indicated that the effectivity of temozolomide as either single or combination therapy in chondrosarcoma is not determined by the IDH mutation status and may be associated with other molecular differences between cell lines, such as MGMT expression. This evidence concerns the gene IDH2 and chondrosarcoma.